150 related articles for article (PubMed ID: 37523331)
21. Utilizing lesion diameter and prostate specific antigen density to decide on magnetic resonance imaging guided confirmatory biopsy of prostate imaging reporting and data system score three lesions in African American prostate cancer patients managed with active surveillance.
Alanee S; Deebajah M; Dabaja A; Peabody J; Menon M
Int Urol Nephrol; 2022 Apr; 54(4):799-803. PubMed ID: 35138582
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic Accuracy and Prognostic Value of Serial Prostate Multiparametric Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer.
Chu CE; Cowan JE; Lonergan PE; Washington SL; Fasulo V; de la Calle CM; Shinohara K; Westphalen AC; Carroll PR
Eur Urol Oncol; 2022 Oct; 5(5):537-543. PubMed ID: 33483265
[TBL] [Abstract][Full Text] [Related]
23. Cognitive MRI-TRUS fusion-targeted prostate biopsy according to PI-RADS classification in patients with prior negative systematic biopsy results.
Lai WJ; Wang HK; Liu HT; Park BK; Shen SH; Lin TP; Chung HJ; Huang YH; Chang YH
J Chin Med Assoc; 2016 Nov; 79(11):618-624. PubMed ID: 27567440
[TBL] [Abstract][Full Text] [Related]
24. Comparison of PSA density and lesion volume strategies for selecting men with equivocal PI-RADS 3 lesions on bpMRI for biopsies.
Kortenbach KC; Løgager V; Thomsen HS; Boesen L
Abdom Radiol (NY); 2023 Feb; 48(2):688-693. PubMed ID: 36318331
[TBL] [Abstract][Full Text] [Related]
25. Biparametric Quantitative MRI for Prostate Cancer Detection.
Uyanik M; Vigneswaran HT; Hale GR; Gann P; Magin R; Abern MR
Top Magn Reson Imaging; 2023 Dec; 32(6):66-72. PubMed ID: 38051029
[TBL] [Abstract][Full Text] [Related]
26. Can we omit systematic biopsies in patients undergoing MRI fusion-targeted prostate biopsies?
Leow JJ; Koh SH; Chow MW; Loke W; Salada R; Hong SK; Yeow Y; Lee CH; Tan CH; Tan TW
Asian J Androl; 2023; 25(1):43-49. PubMed ID: 35488666
[TBL] [Abstract][Full Text] [Related]
27. Biomarker vs MRI-Enhanced Strategies for Prostate Cancer Screening: The STHLM3-MRI Randomized Clinical Trial.
Björnebo L; Discacciati A; Falagario U; Vigneswaran HT; Jäderling F; Grönberg H; Eklund M; Nordström T; Lantz A
JAMA Netw Open; 2024 Apr; 7(4):e247131. PubMed ID: 38648061
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic Accuracy of Single-plane Biparametric and Multiparametric Magnetic Resonance Imaging in Prostate Cancer: A Randomized Noninferiority Trial in Biopsy-naïve Men.
Russo F; Mazzetti S; Regge D; Ambrosini I; Giannini V; Manfredi M; De Luca S; Bollito E; Porpiglia F
Eur Urol Oncol; 2021 Dec; 4(6):855-862. PubMed ID: 33893066
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic value of combining PI-RADS v2.1 with PSAD in clinically significant prostate cancer.
Wei X; Xu J; Zhong S; Zou J; Cheng Z; Ding Z; Zhou X
Abdom Radiol (NY); 2022 Oct; 47(10):3574-3582. PubMed ID: 35788882
[TBL] [Abstract][Full Text] [Related]
30. Transperineal Versus Transrectal MRI/TRUS Fusion Targeted Biopsy: Detection Rate of Clinically Significant Prostate Cancer.
Pepe P; Garufi A; Priolo G; Pennisi M
Clin Genitourin Cancer; 2017 Feb; 15(1):e33-e36. PubMed ID: 27530436
[TBL] [Abstract][Full Text] [Related]
31. Comparison of Multiparametric Magnetic Resonance Imaging-Targeted Biopsy With Systematic Transrectal Ultrasonography Biopsy for Biopsy-Naive Men at Risk for Prostate Cancer: A Phase 3 Randomized Clinical Trial.
Klotz L; Chin J; Black PC; Finelli A; Anidjar M; Bladou F; Mercado A; Levental M; Ghai S; Chang SD; Milot L; Patel C; Kassam Z; Moore C; Kasivisvanathan V; Loblaw A; Kebabdjian M; Earle CC; Pond GR; Haider MA
JAMA Oncol; 2021 Apr; 7(4):534-542. PubMed ID: 33538782
[TBL] [Abstract][Full Text] [Related]
32. Who can safely evade a magnetic resonance imaging fusion-targeted biopsy (MRIFTB) for prostate imaging reporting and data system (PI-RADS) 3 lesion?
Kim M; Ryu H; Lee HJ; Hwang SI; Choe G; Hong SK
World J Urol; 2021 May; 39(5):1463-1471. PubMed ID: 32696126
[TBL] [Abstract][Full Text] [Related]
33. Combining clinical parameters and multiparametric magnetic resonance imaging to stratify biopsy-naïve men for an optimum diagnostic strategy with prostate-specific antigen 4 ng ml
Zhang CC; Tu X; Lin TH; Cai DM; Yang L; Qiu S; Liu ZH; Yang L; Wei Q
Asian J Androl; 2023; 25(4):492-498. PubMed ID: 36571328
[TBL] [Abstract][Full Text] [Related]
34. Unified model involving genomics, magnetic resonance imaging and prostate-specific antigen density outperforms individual co-variables at predicting biopsy upgrading in patients on active surveillance for low risk prostate cancer.
Beksac AT; Ratnani P; Dovey Z; Parekh S; Falagario U; Roshandel R; Sobotka S; Kewlani D; Davis A; Weil R; Bashorun H; Jambor I; Lewis S; Haines K; Tewari AK
Cancer Rep (Hoboken); 2022 Mar; 5(3):e1492. PubMed ID: 34931468
[TBL] [Abstract][Full Text] [Related]
35. Comparison of prostate cancer detection rates between magnetic resonance imaging-targeted biopsy and transrectal ultrasound-guided biopsy according to Prostate Imaging Reporting and Data System in patients with PSA ≥4 ng/mL: a systematic review and meta-analysis.
Zhu K; Qin Z; Xue J; Miao C; Tian Y; Liu S; Zhu S; Gu Q; Hou C; Xu A; Yang J; Wang Z
Transl Androl Urol; 2019 Dec; 8(6):741-753. PubMed ID: 32038971
[TBL] [Abstract][Full Text] [Related]
36. Prostate cancer detection rate in men undergoing transperineal template-guided saturation and targeted prostate biopsy.
Kaufmann B; Saba K; Schmidli TS; Stutz S; Bissig L; Britschgi AJ; Schaeren E; Gu A; Langenegger N; Sulser T; Eberli D; Keller EX; Hermanns T; Poyet C
Prostate; 2022 Feb; 82(3):388-396. PubMed ID: 34914121
[TBL] [Abstract][Full Text] [Related]
37. [Preliminary applicability evaluation of Prostate Imaging Reporting and Data System version 2 diagnostic score in 3.0T multi-parameters magnetic resonance imaging combined with prostate specific antigen density for prostate cancer].
Zuo MZ; Zhao WL; Wei CG; Zhang CY; Wen R; Gu YF; Li MJ; Zhang YY; Wu JF; Li X; Shen JK
Zhonghua Yi Xue Za Zhi; 2017 Dec; 97(47):3693-3698. PubMed ID: 29325321
[No Abstract] [Full Text] [Related]
38. The combined role of MRI prostate and prostate health index in improving detection of significant prostate cancer in a screening population of Chinese men.
Chiu PK; Lam TY; Ng CF; Teoh JY; Cho CC; Hung HY; Hong C; Roobol MJ; Chu WC; Wong SY; Sung JJ
Asian J Androl; 2023 Nov; 25(6):674-679. PubMed ID: 37534902
[TBL] [Abstract][Full Text] [Related]
39. Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers.
Hoeks CM; Schouten MG; Bomers JG; Hoogendoorn SP; Hulsbergen-van de Kaa CA; Hambrock T; Vergunst H; Sedelaar JP; Fütterer JJ; Barentsz JO
Eur Urol; 2012 Nov; 62(5):902-9. PubMed ID: 22325447
[TBL] [Abstract][Full Text] [Related]
40. Should Targeted Biopsy be Performed in Patients Who Have Only Pi-rads 3 Lesions?
Koparal MY; Sözen TS; Karşiyakali N; Akdoğan B; Özen H; Aslan G; Türkeri L
Arch Esp Urol; 2022 Jun; 75(5):410-415. PubMed ID: 35983811
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
